Trial Profile
Phase I-II study of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated doxorubicin (LDox) in patients with HER2 negative metastatic breast cancer (ABRAMYO STUDY)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jul 2014
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Doxorubicin liposomal
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ABRAMYO
- 31 Jul 2014 New trial record